Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 10:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. The major stock market averages all closed up more than 2% for the holiday-shortened week, as an early recovery-play rally gave way to a tech-safety trade...
SOUTH SAN FRANCISCO, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet n...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks ended lower on Friday on raised concerns over the economic impact of the pandemic and the Treasury Department's new curtailing of emergency economic...
Gainers: Alterity Therapeutics (ATHE) +144%.CBAK Energy Technology (CBAT) +47%.Pioneer Power Solutions (PPSI) +47%.HighPoint Resources (HPR) +40%.Foundation Building Materials (FBM) +27%.Maiden (MHLD) +27%.Westwater Resources (WWR) +27%.Canaan (CAN) +24%.HD Supply (HDS) +24%.Tuniu (...
Gainers: Alterity Therapeutics (ATHE) +120%, Outset Medical (OM) +17%, Keros Therapeutics (KROS) +9%, Inovio Pharmaceuticals (INO) +10%, Fulgent Genetics (FLGT) +14%.Losers: RAPT Therapeutics (RAPT) -46%, IMAC Holdings (IMAC) -10%, BioNTech (B...
RAPT Therapeutics (RAPT) slumps 25% premarket despite positive initial data from its ongoing Phase 1/2 trial for FLX475 in multiple cancer indications. Initial observations as of November 10, include preliminary:Evidence of monotherapy activity,Encouraging efficacy in combination wi...
RAPT Therapeutics (RAPT): Q3 GAAP EPS of -$0.60 misses by $0.02.Revenue of $1.53M beats by $0.53M.Shares -24.5% PM.Press Release For further details see: RAPT Therapeutics EPS misses by $0.02, beats on revenue
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet n...
-Evidence of Monotherapy and Combination Activity in Charged Tumor Types- -Company Advances Several Cohorts into Phase 2 Expansions- -Conference Call and Webcast to be Held at 8:30 a.m. ET Today- SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. ...
News, Short Squeeze, Breakout and More Instantly...
RAPT Therapeutics Inc. Company Name:
RAPT Stock Symbol:
NASDAQ Market:
RAPT Therapeutics Inc. Website:
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflamm...
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflamm...
2024-02-23 01:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...